Ocular Surface Treatment to Improve Oculoplastic Interventions

0.75 CME
45 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Ocular Surface treatment

Overview

Provider Statement

This continuing education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by educational grants from Horizon Therapeutics USA, Inc. and Oyster Point Pharma, Inc.


Activity Description

The normal structure and function of the eyelids, eyelashes, conjunctival fornices, and lacrimal system are essential for the health of the ocular surface, and abnormalities of these structures accompany many cases of ocular surface disease (OSD). The eyelid margin is important but currently an overlooked structure that plays an essential role in the health and integrity of the ocular surface and the preocular tear film. Therefore, the health of the ocular surface and eyelids should be optimized prior to any oculoplastic intervention, and abnormalities should be taken into consideration during evaluation and management of patients scheduled for oculoplastic procedures. Achieving this goal includes diagnosing and treating any ocular condition before interventions are performed to reduce complications and improve patient outcomes. In thyroid eye disease (TED), a growing body of research suggests that inflammation and multifactorial changes in the homeostasis of the ocular surface contribute substantially to the OSD seen in TED patients. Dry eye syndrome occurs in up to 85% of patients with TED, and lacrimal gland enlargement correlates with subjective tearing and a reduction in quality of life in patients with TED. Before physicians can consider medical or surgical management of TED, any underlying thyroid abnormalities should be addressed by an endocrinologist. In this educational activity, expert faculty will review the risk factors and best practices for the differential diagnosis of OSD. They will also explore the treatment options for OSD, including those with newer routes of administration of therapy–such as nasal sprays—and for TED, including conventional and biologic therapy, in a case-based discussion designed to illustrate optimal use and practical tips in treating patients with these disorders.


Target Audience

The intended audience for this activity is oculoplastic surgeons, ophthalmologists, and other healthcare professionals involved in the management of patients undergoing oculoplastic procedures.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • List diagnostic strategies that can improve the early detection of ocular surface disorders in patients undergoing oculoplastic procedures.
  • Describe practices, procedures, and treatments for the ocular surface to increase the chances of success of oculoplastic interventions.

Activity Chair

Wendy W. Lee, MD
Professor of Clinical Ophthalmology and Dermatology
Director, Bascom Palmer Aesthetics Center
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL


Faculty

Andrew R. Harrison, MD
Professor, Departments of Ophthalmology and Otolaryngology
Director, Oculoplastic and Orbital Surgery
Co-Director, Center for Thyroid Eye Disease
University of Minnesota
Minneapolis, MN

Sonia H. Yoo MD
Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute
University of Miami
Miller School of Medicine
Miami, FL


Planner/Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

ACCME Jointly accredited In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 15, 2023, to December 14, 2024.


How to Participate in This Activity and Obtain CE Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 6 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Activity Chair and Faculty report the following relevant financial relationship(s)

Andrew R. Harrison, MD
Consultant: Horizon, Lassen
Speaker Contracted by Ineligible Company: Horizon
Independent Research Contractor: Viridian

Wendy W. Lee, MD
Consultant: Allergan, Horizon, Tarsus

Sonia H. Yoo MD
Royalties or Patent Beneficiary: Resolve Ophthalmics
Consultant: Oyster Point, Zeiss

Planner/Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


ADA Compliance:

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this lecture is available upon request. Requests should include the activity title and emailed to CME@VindicoCME.com. Requests will be honored within 3 to 5 business days.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CE Questions?

Contact us at cme@vindicoCME.com